首頁 > 市場調查報告書 > 生物科技 > 基因治療學和RNAi > RNA干涉（RNAi）的治療適應 - 2011～2021年的市場展望

聯絡我們?

市場調查報告書

RNA干涉（RNAi）的治療適應 - 2011～2021年的市場展望

RNAi for Therapeutic Applications: Market Prospects 2011-2021

出版商	Visiongain
出版日期	2011年03月	商品編碼	191129
內容資訊	英文 152 Pages
價格	US $ 2331 PDF by E-mail (Single user license) US $ 4663 PDF by E-mail (Department License) US $ 7772 PDF by E-mail (Site license) US $ 10882 PDF by E-mail (Global license)

簡介
目錄
相關商品

RNA干涉（RNAi）的治療適應 - 2011～2021年的市場展望 是由出版商Visiongain在2011年03月所出版的。這份英文市場調查報告書包含152 Pages 價格從美金2331起跳。

簡介

本報告書內容包括:RNA干涉（RNAi）的治療適應之調查分析、相關產品及其製造的企業趨勢彙整、以及2011～21年的展望、內容綱要摘記如下:

第1章實施摘要

關於RNA干渉（RNAi）市場
本報告書的目的、範圍、形式
調查分析的方法

第2章介紹

RNA的全球
RNAi的歷史：發現起6年中的臨床試驗
RNA干涉（RNAi）
- 細胞内基因沉默的自然過程
- RNAi的内因性過程：RNAi的'機械設備'
- RNAi誘導因素
RNAi和治療的潛在性
- RNAi基礎的治療藥開發
- 採用RNAi療法的首次企業的成立：Ribopharma到Roche Kulmbach

第3章 2011年的RNAi發展：技術及活動

RNAi療法開發所相關的很多企業
市場分類：對企業來說的差異對策
主要製藥公司的加入
- Merck的Sirna Therapeutics收購受到大企業的關心
- Roche的RNAi領域的撤退：是否會失去大企業的關心？
- 夥伴精神從技術平台到產品平台
RNAi相關專利的相關展望：Alnylam Pharmaceuticals的優勢
RNAi療法開發的生產線
- 一部份臨床試驗結束
- RNAi療法開發的第2階段之現況
- RNAi誘導因素的人氣高的合成siRNA

第4章 2011～21年的RNAi治療之全球市場

RNAi治療藥：2011～21年的全球市場之銷售預測
- 範圍和界線
- 市場預測之相關假設
- 市場預測：樂觀的發展情境
- 市場預測：悲觀的發展情境
2021年的RNAi治療藥市場所先行引導的治療領域
- 眼科疾病
- 肺／呼吸器疾病
- 肝臟疾病
- 腎疾病：腎臟移植後的功能降低
- 家族性大腸腺腫症（FAP）
RNAi治療藥市場的銷售預測：2014～21年的主要市場

第5章 2011年時的主要企業

Alnylam Pharmaceuticals
Silence Therapeutics
OPKO Health
Quark Pharmaceuticals
Merck & Co.
Tekmira Pharmaceuticals Corporation
Calando Pharmaceuticals
Sylentis
Gradalis

第6章 2011年時所開發中的RNAi基礎治療藥

FANG疫苗（Gradalis）
SYL040012（Sylentis）
CALAA-01（Calando Pharmaceuticals）
TKM-ApoB（Tekmira Pharmaceuticals）
Bevasiranib/Cand5（OPKO Health）
RTP801i-14/PF-4523655（Pfizer/Quark Pharmaceuticals）
QPI-1002（Quark Pharmaceuticals）
AGN-745/SIRNA-027（Allergan/Merck & Co.）
ALN-RSV01（Alnylam Pharmaceuticals/Cubist Pharmaceuticals/•Kyowa Hakko Kirin Co.,Ltd）
ALN-VSP02（Alnylam Pharmaceuticals）
Atu027（Silence Therapeutics）

第7章 2011～21年的RNAi市場所持有的問題點

RNAi領域的優點和缺點
機會和威脅

第8章業界的見解

第9章彙整

You will receive hard data for the RNAi-based therapeutics industry and market - especially our revenue forecasts to 2021
You will review the RNAi therapies R&D pipeline, assessing its potential
You will discover revenue predictions for the overall market from 2011 to 2021 - seeing where commercial growth will occur
You will see the revenue prospects for the eight leading RNAi agents to 2021, with discussions of market potential and competition
You will find revenue prospects for leading geographical markets to 2021 (US, Japan and EU5 group)
You will assess leading companies in RNAi-based therapeutics, discovering their activities and outlooks
You will investigate competition and opportunities that will influence the RNAi-based treatments field
You will see what will stimulate and restrain the RNAi products industry and market
You will view opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. The emphasis is on future revenue trends - distinctive predictions from our work. Our independent analysis helps you to stay ahead in commercial knowledge for RNAi technologies.

Order our report now to gain industry and market information you need

Our report can benefit everybody interested in product development, services and market analysis for RNAi technologies. We give predictions and answers you need. Don' t miss out - please order our report now.

1. Executive Summary

1.1 RNAi Therapeutics Market Review
1.2 Aims, Scope and Format of the Report
- 1.2.1 Speculative Aspects of Assessing the RNAi Therapeutics Market
- 1.2.2 Chapter Outlines
1.3 Research and Analysis Methods

2. Introduction

2.1 The RNA World
2.2 Timeline of RNAi: From Discovery to Human Trials in Six Years
2.3 RNA Interference (RNAi)
- 2.3.1 A Natural Cellular Gene Silencing Process
- 2.3.2 The Endogenous Process of RNAi: The RNAi Machinery
- 2.3.3 RNAi Inducers
  - 2.3.3.1 Short or Small Interfering RNA (siRNA)
  - 2.3.3.2 microRNA (miRNA)
2.4 RNAi and Its Therapeutic Potential
- 2.4.1 Development of RNAi-Based Therapeutic Agents
  - 2.4.1.1 Following the Delivery Approach
  - 2.4.1.2 Expressed Approach/ DNA-directed RNAi (ddRNAi): A Stable Expression of RNAi Inducers
    - 2.4.1.2.1 Short Hairpin RNA (shRNA)
- 2.4.2 Setting up of the First Company for RNAi Therapeutics: From Ribopharma AG to Roche Kulmbach GmbH

3. The Emerging RNAi Therapeutics Industry in 2011: Technologies and Activities

3.1 RNAi Therapies Are Being Developed by Many Companies
3.2 Market Segmentation: Companies Take Different Approaches to Achieve RNAi
3.3 The Participation of Leading Pharma Companies
- 3.3.1 Merck' s Acquisition of Sirna Therapeutics Generated Interest Among Large Pharmaceutical Companies
- 3.3.2 Recent Exit of Roche from the RNAi Field: Are Major Pharmaceutical Companies Losing Interest?
- 3.3.3 From Partnerships for Technology Platforms to Product Platforms
3.4 The RNAi Patent Landscape: Dominated by Alnylam Pharmaceuticals
3.5 The RNAi Therapeutics Development Pipeline
- 3.5.1 Termination of Some Clinical Trials
- 3.5.2 Phase II is the Latest Stage of Development for RNAi Therapeutics
- 3.5.3 Synthetic siRNAs are Currently the Most Popular RNAi Inducers

4. Global Market for RNAi Therapeutics, 2011-2021

4.1 RNAi Therapeutics: World Sales Forecast, 2011-2021
- 4.1.1 Scope and Limitations
- 4.1.2 Assumptions for Market Forecast
- 4.1.3 RNAi Therapeutics Market Forecast: Optimistic Scenario
- 4.1.4 RNAi Therapeutics Market Forecast: Pessimistic Scenario
4.2 Therapeutic Areas Driving the RNAi Therapeutics Market to 2021
- 4.2.1 Ophthalmic Disorders
  - 4.2.1.1 Retinal Disorders: Age-Related Macular Degeneration (AMD)
  - 4.2.1.2 Current Treatment Options for AMD
  - 4.2.1.3 Future Outlook of RNAi Therapeutics for Retinal Disorders
  - 4.2.1.4 Sales Forecast for Bevasiranib and PF-655, 2011-2021: Strong Entry Barriers
  - 4.2.1.5 Glaucoma
  - 4.2.1.6 Current Treatment Options for Glaucoma
  - 4.2.1.7 Sales Forecast for SYL040012, 2011-2021: Strong Competition in the Market
- 4.2.2 Lung/Respiratory Disorders
  - 4.2.2.1 Asthma
  - 4.2.2.2 Current Treatment Options for Asthma
  - 4.2.2.3 Sales Forecast for Excellair, 2011-2021: Strong Competition in the Market
  - 4.2.2.4 Respiratory Syncytial Virus (RSV) Infection
  - 4.2.2.5 Current Treatment Options for Treatment of RSV Infection
  - 4.2.2.6 Sales Forecast for ALN-RSV01, 2011-2021: RNAi Therapeutics Looking to Expand the RSV Treatment Market
- 4.2.3 Liver Disorders
  - 4.2.3.1 Hepatitis C Virus (HCV) Infection
  - 4.2.3.2 Current Treatment Options for HCV Infection
  - 4.2.3.3 Sales Forecast for Miravirsen, 2011-2021: Unmet Needs in the Market
- 4.2.4 Kidney Diseases: Delayed Graft Function Associated with Kidney Transplantation
  - 4.2.4.1 Current Treatment Options for Prevention of DGF: Unmet Medical Need
  - 4.2.4.2 Sales Forecast for QPI-1002, 2011-2021: High Potential for RNAi Therapeutics in Preventing DGF
- 4.2.5 Familial Adenomatous Polyposis (FAP)
  - 4.2.5.1 Current Treatment Options for FAP
  - 4.2.5.2 Sales Forecast for CEQ508, 2011-2021: High Potential for RNAi Therapeutics in FAP Treatment
4.3 Sales Forecasts for RNAi Therapeutics Market: Leading National Markets, 2014-2021

5. Leading Companies in the RNAi Therapeutics Industry, 2011

5.1 Alnylam Pharmaceuticals
- 5.1.1 A Leading Company in the RNAi Therapeutics Industry
- 5.1.2 A Strong Portfolio in the RNAi Field
- 5.1.3 Entering Into Strategic Alliances to Generate Revenues
- 5.1.4 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
- 5.1.5 Financial Performance
- 5.1.6 Future Growth Strategy
5.2 Silence Therapeutics
- 5.2.1 Overview
- 5.2.2 A Strong Position in the Market: Granted by Proprietary AtuRNAi Technology and Multiple Delivery Technologies
- 5.2.3 The Lead Candidate Atu027 Expected to Complete Phase I in 2011
- 5.2.4 Partnerships for Silence Therapeutics' RNAi Platform
- 5.2.5 Financial Performance
5.3 OPKO Health
- 5.3.1 Profile
- 5.3.2 OPKO Health Adds New siRNA Molecules to its RNAi Space
5.4 Quark Pharmaceuticals
- 5.4.1 Profile
- 5.4.2 A Broad siRNA Clinical Pipeline
- 5.4.3 Quark has Entered into Several Partnerships for Developing and Promoting its RNAi-Based Therapies
5.5 Merck & Co.
- 5.5.1 Profile
- 5.5.2 Merck Acquired Sirna Therapeutics to Enter the RNAi Therapeutics Space
- 5.5.3 Undisclosed RNAi Programme
5.6 Tekmira Pharmaceuticals Corporation
- 5.6.1 Profile
- 5.6.2 Proprietary Technology and Manufacturing Services: A Source of Revenues
- 5.6.3 Progressing LNP Based siRNA Drug Candidates to Clinical Development
- 5.6.4 Financial Performance
5.7 Calando Pharmaceuticals
- 5.7.1 Overview
- 5.7.2 Company Focus: A Nanoparticle-Based Drug Delivery Platform
- 5.7.3 Calando' s Change in Business Strategy
5.8 Sylentis
- 5.8.1 Overview
- 5.8.2 The First Company in Spain to Conduct Clinical Trial of an RNAi Agent
5.9 Gradalis
- 5.9.1 Overview
- 5.9.2 Company Pipeline: Vaccine Based on shRNA in Clinical Development

6. RNAi-Based Therapeutic Agents in Development, 2011

6.1 FANG Vaccine (Gradalis)
- 6.1.1 The First RNAi-Based Vaccine in Development
- 6.1.2 Phase I Clinical Trial Initiated
6.2 SYL040012 (Sylentis)
- 6.2.1 Lead Product Candidate of Sylentis: A Suitable Mode of Administration
- 6.2.2 In Phase I/II for an Ophthalmic Condition
6.3 CALAA-01 (Calando Pharmaceuticals)
- 6.3.1 The Lead Product Candidate of Calando Pharmaceuticals
- 6.3.2 Preliminary Results for Phase I Clinical Trial: CALAA-01 is Well Tolerated
6.4 TKM-ApoB (Tekmira Pharmaceuticals)
- 6.4.1 Overview
- 6.4.2 Clinical Development Stalled After Phase I Human Trials
- 6.4.3 Strong Competition from an Antisense Product Candidate
6.5 Bevasiranib/Cand5 (OPKO Health)
- 6.5.1 Overview
- 6.5.2 Bevasiranib to Benefit or Face Competition from Lucentis?
- 6.5.3 OPKO Health Terminates the Phase III Clinical Trial of Bevasiranib
6.6 RTP801i-14/PF-4523655 (Pfizer/Quark Pharmaceuticals)
- 6.6.1 Description
- 6.6.2 Pfizer is the Development Partner for PF-655
- 6.6.3 Phase II Trial Terminated for DME
6.7 QPI-1002 (Quark Pharmaceuticals)
- 6.7.1 First Systemically Administered siRNA Drug to be Tested in Human Beings
- 6.7.2 QPI-1002 Receives Orphan Drug Status
- 6.7.3 Discovery and Development History
6.8 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
- 6.8.1 A Promising RNAi-Based Drug Candidate acquired from Sirna Therapeutics
- 6.8.2 Allergan Halts Drug Development
- 6.8.3 A Setback to the Hope for RNAi-Based Treatment of AMD
6.9 ALN-RSV01 (Alnylam Pharmaceuticals/Cubist Pharmaceuticals/Kyowa Hakko Kirin)
- 6.9.1 The Lead Candidate Drug of Alnylam Pharmaceuticals
- 6.9.2 ALN-RSV01 Advances into Phase IIb
- 6.9.3 Partnership for Development of ALN-RSV Programme
6.10 ALN-VSP02 (Alnylam Pharmaceuticals)
- 6.10.1 Alnylam' s First Clinical Programme in Oncology
- 6.10.2 Alnylam Presented Preliminary Data for ALN-VSP02 Phase I Study
6.11 Atu027 (Silence Therapeutics)
- 6.11.1 Product Overview
- 6.11.2 Atu027: One of the Most Advanced RNAi Therapeutic Agents for Cancer

7. Issues Affecting the RNAi Industry and Market, 2011-2021

7.1 Strengths and Weakness of the Sector
- 7.1.1 Therapeutic Targeting
- 7.1.2 Specificity and Efficiency: Low Amounts of RNAi Therapeutic Should Be Effective
- 7.1.3 Shorter Lead Identification Times: Providing Edge over Other Approaches
- 7.1.4 Manufacturing Synthetic RNAs: Cost Effective and Easier Than Biologics
- 7.1.5 Delivery Challenges
  - 7.1.5.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
  - 7.1.5.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
  - 7.1.5.3 Industry Approach to Meet the Delivery Challenges
- 7.1.6 Off-target Binding, Immune Response and Oversaturation of the Silencing Machinery Leading to Side Effects
7.2 Opportunities and Threats
- 7.2.1 Competing Technologies
  - 7.2.1.1 Antisense Technology: First-to-Market Advantage
  - 7.2.1.2 Aptamers
- 7.2.2 Regulatory Threats
- 7.2.3 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
- 7.2.4 Opportunities for the Treatment of Multifactor Diseases

8. Opinion from Our Industry Survey

8.1 Authority from a Company in the Sector (Views Provided Anonymously), Silence Therapeutics
- 8.1.1 Silence Therapeutics' Lead Pipeline Drug Candidate: Atu027
- 8.1.2 Silence Therapeutics' Other Pipeline Drugs
- 8.1.3 Key Threats Facing the RNAi Therapeutics Market
- 8.1.4 On Partnerships for the Development of RNAi Therapeutics
- 8.1.5 The Future of RNAi Therapeutics Development
8.2 Interview with Dr John Nemunaitis, Chief Medical Officer and Founder, Gradalis
- 8.2.1 Gradalis' Lead Compound in Development - FANG Vaccine
- 8.2.2 Gradalis' Other Pipeline Drugs
- 8.2.3 Key Threats Facing the RNAi Therapeutics Market
- 8.2.4 Major Growth Opportunities for the Development of RNAi Therapeutics

9. Conclusions

9.1 RNAi: Fast-Advancing Field with Therapeutic and Commercial Potential
9.2 Optimistic vs. Pessimistic View of the RNAi Therapeutics Market
9.3 Future Outlook for the RNAi Therapeutics Market

List of Tables

Table 2.1: Advantages and Disadvantages of Using Synthetic siRNAs as Therapeutic Agents
Table 2.2: Advantages of ddRNAi over siRNA
Table 3.1: Companies Developing RNAi Therapeutic Agents, 2011
Table 3.2: Some Transactions in the RNAi Therapeutics Market, 2011
Table 3.3: RNAi-Based Therapeutics in Clinical Development: Drug Candidates from Industry and Academic Organisations, 2011
Table 3.4: RNAi-Based Therapeutics in Preclinical Development and Discovery Stages: Drug Candidates from Industry and Academic Organisations, 2011
Table 3.5: Share (%) of RNAi Studies by Stage of Development, 2011
Table 3.6: Share (%) of RNAi-Based Therapeutics by RNAi Approach, 2011
Table 4.1: Expected Launches of RNAi Therapeutics Currently in Phase II and III Clinical Development
Table 4.2: RNAi Therapeutics: Market Forecasts ($m), 2011-2021: Optimistic Scenario
Table 4.3: RNAi Therapeutics: Market Forecasts ($m), 2011-2021: Pessimistic Scenario
Table 4.4: RNAi Therapeutics Clinical Pipeline for Ocular Diseases
Table 4.5: Sales ($m) Forecast for Bevasiranib and PF-655, 2011-2021: Optimistic Scenario
Table 4.6: Sales ($m) Forecast for Bevasiranib and PF-655, 2011-2021: Pessimistic Scenario
Table 4.7: Sales ($m) Forecast for SYL040012, 2011-2021: Optimistic Scenario
Table 4.8: Sales ($m) Forecast for SYL040012, 2011-2021: Pessimistic Scenario
Table 4.9: RNAi Therapeutics Clinical Pipeline for Respiratory Diseases
Table 4.10: Sales ($m) Forecast for Excellair, 2011-2021: Optimistic Scenario
Table 4.11: Sales ($m) Forecast for Excellair, 2011-2021: Pessimistic Scenario
Table 4.12: Sales ($m) Forecast for ALN-RSV01, 2011-2021
Table 4.13: Sales ($m) Forecast for Miravirsen, 2011-2021
Table 4.14: Sales ($m) Forecast for QPI-1002, 2011-2021
Table 4.15: Sales ($m) Forecast for CEQ508, 2011-2021
Table 4.16: RNAi Therapeutics: Sales ($m) in Leading National Markets, 2014, 2017 & 2021
Table 4.17: Market Shares (%) of the Leading National Markets, 2014, 2017 & 2021
Table 5.1: Alnylam Pharmaceuticals' RNAi Drug Pipeline, 2011
Table 5.2: Financial Performance, Alnylam Pharmaceuticals, 2008 & 2009
Table 5.3: Silence Therapeutics' RNAi Drug Pipeline, 2011
Table 5.4: Financial Performance, Silence Therapeutics, 2008 & 2009
Table 5.5: Quark Pharmaceutical' s RNAi Drug Pipeline, 2011
Table 5.6: Tekmira Pharmaceutical' s RNAi Drug Pipeline, 2011
Table 5.7: Financial Performance, Tekmira Pharmaceuticals, 2008 & 2009
Table 5.8: Advantages of Calando Pharmaceuticals RONDEL siRNA Delivery Technology
Table 5.9: Sylentis' RNAi Drug Pipeline, 2011
Table 5.10: Gradalis' RNAi Vaccine and Drug Pipeline, 2011
Table 7.1: SWOT Analysis of the RNAi Therapeutics Industry and Market, 2011-2021
Table 7.2: Some Contract Manufacturing Organisations for Oligonucleotide APIs, 2011
Table 7.3: Advantages of Local Delivery over Systemic Delivery
Table 7.4: Companies Developing Delivery Systems/Technologies for the Delivery of RNAi-based Drugs, 2011
Table 7.5: Development of Antisense Drugs: Some Companies and Clinical Candidates, 2011
Table 7.6: Development of Aptamer Drugs: Some Companies and Clinical Candidates, 2011
Table 9.1: RNAi Therapeutics Market Forecast ($m), 2014, 2017 & 2021: Optimistic vs. Pessimistic Scenario

List of Figures

Figure 2.1: The Basic Process of RNA Interference
Figure 2.2: Model of RNA Interference: Cleavage Dependent Mechanism
Figure 3.1: Segmentation of the RNAi-based Therapeutics, 2011
Figure 3.2: Shares (%) of RNAi Studies by Stage of Development, 2011
Figure 3.3: Shares (%) of RNAi-based Therapeutics by RNAi Approach, 2011
Figure 4.1: RNAi Therapeutics Market Forecast ($m), 2011-2021: Optimistic Scenario
Figure 4.2: Sales ($m) Forecast for RNAi Pipeline Drugs, 2011-2021: Optimistic Scenario
Figure 4.3: RNAi Therapeutics Market Forecast ($m), 2011-2021: Pessimistic Scenario
Figure 4.4: Sales ($m) Forecast for RNAi Pipeline Drugs, 2011-2021: Pessimistic Scenario
Figure 4.5: Sales ($m) Forecast for Bevasiranib and PF-655, 2011-2021: Optimistic vs. Pessimistic Scenario
Figure 4.6: Sales ($m) Forecast for SYL040012, 2011-2021: Optimistic vs. Pessimistic Scenario
Figure 4.7: Sales ($m) Forecast for Excellair, 2011-2021: Optimistic vs. Pessimistic Scenario
Figure 4.8: Sales ($m) Forecast for ALN-RSV01, 2011-2021
Figure 4.9: Sales ($m) Forecast for Miravirsen, 2011-2021
Figure 4.10: Sales ($m) Forecast for QPI-1002, 2011-2021
Figure 4.11: Sales ($m) Forecast for CEQ508, 2011-2021
Figure 4.12: RNAi Therapeutics: Sales ($m) in Leading National Markets, 2014, 2017 & 2021: Optimistic Scenario
Figure 4.13: RNAi Therapeutics: Sales ($m) in Leading National Markets, 2014, 2017 & 2021: Pessimistic Scenario
Figure 4.14: Market Shares (%) of the Leading National Markets, 2014, 2017 & 2021
Figure 9.1: RNAi Therapeutics Market Forecast ($m), 2014, 2017 & 2021: Optimistic vs. Pessimistic Scenario

Companies Listed

Abbott
Acuity Pharmaceuticals
Aegera Therapeutics
Agilent Technologies
Alcon
Alimera Sciences
Allele Biotechnology
Allergan
Alnylam Pharmaceuticals
Altogen Labs
Antisense Pharma
Antisense Therapeutics
Antisoma Research
Archemix Corporation
ArmaGen Technologies
Arrowhead Research Corporation
AstraZeneca
Asuragen
Atlantic Pharmaceuticals
AtugenAG
Avecia OligoMedicines
AVI BioPharma
Bayer HealthCare
Benitec
Bio Synthesis
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
BioMolecular Therapeutics
Bionexus
BioSpring
Bristol-Myers Squibb (BMS)
Calando Pharmaceuticals
California Institute of Technology
Carnegie Institution for Science
Center of Excellence for RNA Therapeutics
Cequent Pharmaceuticals
Cerulean Pharma
CHDI Foundation
City of Hope National Medical Center
Commonwealth Scientific and Industrial Research Organisation (CSIRO)
Cubist Pharmaceuticals
CytRX Corporation
Dainippon Sumitomo
Danube Pharmaceuticals
Debiopharm
Dharmacon RNAi Technologies
Dicerna Pharmaceuticals
Duke University
Eleos
Eli Lilly
Enzo Therapeutics
Eurofins MWG-Biotech
Eurogentec
European Medicines Agency (EMA)
eXegenics
Expression Genetics
Eyetech Pharmaceuticals
EZBiolab
Federal Institute for Drugs and Medical Devices (BfArM)
Food and Drug Administration (US FDA)
Froptix
Gene Link
Gene Signal International
GeneCare Research Institute
GeneDesign
Genentech
Genesis Research and Development Corporation
Genta Incorporated
Genzyme
Girindus America (a part of Solvay Group)
GlaxoSmithKline (GSK)
Gradalis
Halo-Bio RNAi Therapeutics
IDEC Pharmaceuticals
Independent Data Monitoring Committee
Integrated DNA Technologies
Intradigm Corporation
Invitrogen
Isis Pharmaceuticals
Johnson & Johnson
Kylin Therapeutics
Kyowa Hakko Kirin
Lorus Therapeutics
Lundbeck
Marina Biotech
Mary Crowley Cancer Research Center
Massachusetts Institute of Technology (MIT)
Max Planck Institute
MDRNA
MedImmune
Medtronic
Merck & Co.
miRagen Therapeutics
Mirna Therapeutics
Mirrx Therapeutics
Mitsubishi Tanabe Pharma
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Health and Clinical Excellence (NICE)
Nitto Denko
Novartis Institutes for BioMedical Research (NIBR)
Novartis International
NovaRx Corporation
Novosom
Noxxon Pharma
Ohio State University (OSU)
Oligoengine
OncoGenex Technologies
Oncolys BioPharma
Ophthotech Corporation
OPKO Health
PARI Pharma
Pfizer
Protiva Biotherapeutics
Qiagen
QLT
Quark Pharmaceuticals
Regado Biosciences
Regeneron Pharmaceuticals
Regulus Therapeutics
Ribopharma
RiboTask
Roche
Roche Kulmbach
Rosetta Genomics
Rosetta Inpharmatics
RXi Pharmaceuticals Corporation
SABiosciences
Sanofi-Aventis
Santaris Pharma
Santen Pharmaceuticals
Schering-Plough
Senesco Technologies
Sigma Aldrich
Silence Therapeutics
Silenseed
Sirna Therapeutics
Sirnaomics
Solirna Biosciences
Spanish Medicines and Health Products Agency
Sylentis
Tacere Therapeutics
Takeda Pharmaceutical Company
Targeted Genetics Corporation
Tekmira Pharmaceuticals
Teva Pharmaceuticals
The University of Massachusetts
The University of Massachusetts Medical School (UMMS)
The University of Texas MD Anderson Cancer Center
The Whitehead Institute for Biomedical Research
Thermo Scientific
TransDerm
Traversa Therapeutics
University of Bayreuth
University of Bochum
University of New South Wales
University of Queensland
US Government
Vertex Pharmaceuticals
VIRxSYS
World Health Organization (WHO)
ZaBeCor Pharmaceuticals
Zeltia Group

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp